The Valley Desk

NCT07776691 · Interventional trial

A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)

Overall registry status Recruiting

Phase 3

Conditions Fallopian Tube Cancer, Ovarian Cancer, Ovarian Neoplasms, Peritoneal Cancer

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov